Mito-DHH chloride
Mito-DHH chloride is a mitochondria-targeted catechol-type diphenylhexatriene. Mito-DHH chloride rapidly accumulates in mitochondria and undergoes auto-oxidation in the alkaline mitochondrial matrix to generate ROS. Mito-DHH chloride triggers ROS-dependent reduction of ATP levels via dual inhibition of mitochondrial oxidative phosphorylation and glycolytic metabolism, and induces selective apoptosis in cancer cells. Mito-DHH chloride can be used in research related to lung cancer, liver cancer, malignant melanoma, and colon cancer.
For research use only. We do not sell to patients.
- Formula: C40H38ClO3P
- Molecular Weight:633.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Mito-DHH (0.25-2.8 μM; 48 h) potently and selectively kills A549, HepG2, A375, and SW620 cancer cells over normal L02 cells, with the highest potency against A549 cells (IC50 = 0.25 μM) and a selectivity index of 11.2[1].
Mito-DHH (0.25-0.5 μM; 10 days) impairs long-term clonogenic survival of A549 cells at concentrations of 0.25 μM and 0.5 μM[1].
Mito-DHH (1 μM; 0.5-3 h) rapidly and selectively accumulates in the mitochondria of A549 cells within 0.5 h, with minimal enrichment in L02 cell mitochondria[1].
Mito-DHH (50 μM; 2 h) under alkaline conditions (pH 8 and 10) promotes auto-oxidation to generate reactive oxygen species, with more robust ROS production at higher pH[1].
Mito-DHH (1 μM; 2 h) preferentially induces mitochondrial superoxide anion generation in A549 cells over L02 cells after 2 h of treatment[1].
Mito-DHH (1 μM; 3 h) preferentially induces intracellular hydroxyl radical generation in A549 cells over L02 cells after 3 h of treatment[1].
Mito-DHH (1-2 μM; 6-12 h) induces a ROS-dependent reduction in ATP production in A549 cells after 6 and 12 h, with no effect on ATP levels in L02 cells at 10 μM[1].
Mito-DHH (2 μM; 5 h) inhibits both mitochondrial oxidative phosphorylation and cytoplasmic glycolysis in A549 cells after 5 h of treatment, inducing a dual-effect energy crisis[1].
Mito-DHH (1-2 μM; 18-24 h) preferentially disrupts mitochondrial membrane potential in A549 cells after 18 and 24 h of treatment, with no effect on L02 cells[1].
Mito-DHH (10 μM; 1-12 h) induces late-stage apoptosis in A549 cells, with detectable PI nuclear localization starting at 6 h and progressing over time[1].
Mito-DHH (1-2 μM; 48 h) preferentially induces apoptosis in A549 cells over L02 cells after 48 h of treatment[1].
Mito-DHH (1-2 μM; 24 h) preferentially induces G0/G1 cell cycle arrest in A549 cells over L02 cells after 24 h of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human lung cancer A549 cells
-
Concentration:0.25 μM; 0.5 μM
-
Incubation Time:10 days, with medium replacement every 48 h
-
Result:Significantly suppressed clonogenic survival, with colony counts of 83.5 (0.25 μM) and 61 (0.5 μM), compared to 138.8 in the control group.
-
Cell Line:human lung cancer A549 cells, normal human liver L02 cells
-
Concentration:1 μM
-
Incubation Time:0.5 h; 3 h
-
Result:Showed strong overlap with MitoTracker Deep Red in A549 cells, with a Pearson's colocalization coefficient of 0.91 at 0.5 h, indicating full mitochondrial localization within 30 min.
Displayed limited mitochondrial enrichment in L02 cells.
-
Cell Line:human lung cancer A549 cells
-
Concentration:10 μM
-
Incubation Time:1 h, 6 h, 9 h, 12 h
-
Result:Showed no PI nuclear localization at 1 h; exhibited prominent red fluorescence (PI entry) in nuclei at 6 h, indicating late-stage apoptosis, with nearly complete PI nuclear localization after longer incubation.
-
Cell Line:human lung cancer A549 cells, normal human liver L02 cells
-
Concentration:1 μM, 2 μM
-
Incubation Time:48 h
-
Result:Induced significant apoptosis in A549 cells, with 14.5% early apoptosis and 49.0% late apoptosis at 2 μM.
Induced no significant apoptosis in L02 cells.
-
Cell Line:human lung cancer A549 cells, normal human liver L02 cells
-
Concentration:1 μM, 2 μM
-
Incubation Time:24 h
-
Result:Arrested the cell cycle of A549 cells at the G0/G1 phase, with no significant effect on L02 cell cycle distribution.
Chemical Information
-
Molecular Weight 633.15
-
Formula C40H38ClO3P
-
SMILES
OC1=CC=C(/C=C/C=C/C=C/C2=CC=C(OCCCC[P+](C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=CC=C5)C=C2)C=C1O.[Cl-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)